#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Medulloblastoma recurrent Facioscapulohumeral muscular dystrophy Glioma Duchenne muscular dystrophy SAPHO syndrome Henoch-Schonlein purpura nephritis B-cell lymphoma Chondrosarcoma metastatic Acute myeloid leukaemia Glycogen storage disease type I Acute myeloid leukaemia recurrent Nasopharyngeal cancer Insulinoma Raynaud's phenomenon Huntington's disease More trials…

    Learn about Rare Diseases

    Nodal marginal zone B-cell lymphoma – Trials in Disease Amyotrophic lateral sclerosis Hepatoblastoma – Diagnostics Alveolar rhabdomyosarcoma – Trials in Disease Hereditary hypophosphataemic rickets – Diagnostics Uterine leiomyosarcoma – Trials in Disease Synovial sarcoma metastatic – Trials in Disease Angiosarcoma metastatic – Diagnostics Splenic marginal zone lymphoma – Treatment Angelman’s syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ATUMELNANT Clindamycin Phosphate Olopatadine Hydrochloride Rigosertib Sodium Meropenem Trihydrate Eftilagimod Alfa Granisetron AZD5148 [11C]Az14193391 ROC-101 HYDROCHLORIDE Pyridoxine Hydrochloride E.coli Polysaccharide Nelivaptan IMMUNOSTEM Eo2318 Abt-494 SAR445399 Sotagliflozin Zalunfiban Kd050 More therapies…

    Learn about Your Condition

    Demyelination Hernia repair Haemorrhage prophylaxis Metastases to meninges Alagille syndrome BRAF gene mutation Malignant peritoneal neoplasm KBG syndrome Keratosis follicular Cytokine release syndrome Contusion Intracranial calcification Ewing's sarcoma Juvenile spondyloarthritis Thymic carcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Pia Fondazione Di Culto E Religione Card G Panico

Pia Fondazione Di Culto E Religione Card G Panico

Via Pio X 4, Tricase, 73039, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Temozolomide and Irinotecan for Patients with Stage II/III Colorectal Cancer and Positive ctDNA After Chemotherapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma of colon
    Investigated Drugs:
    • Irinotecan Hydrochloride
    • Temozolomide
    Italy

  • Study of Pembrolizumab, Dendritic Cell Vaccine, Trifluridine/Tipiracil, and Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Autologous Tumor Lysate-Loaded Dendritic Cells
    • Bevacizumab
    • Pembrolizumab
    Italy

  • Study Comparing FOLFIRI with Cetuximab or Bevacizumab for First-Line Treatment in Patients with Metastatic Colorectal Cancer and Specific Genetic Profiles

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Cetuximab
    Italy

  • Study on the Effectiveness of Durvalumab and Bevacizumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Bevacizumab
    • Dextrose Bp
    • Durvalumab
    Austria France Germany Italy Poland

  • Study on Intermittent vs. Continuous Panitumumab and FOLFIRI for Patients with Unresectable Left-Sided Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Panitumumab
    Italy

  • Long-Term Safety Study of ACP-204 for Adults with Alzheimer’s Disease Psychosis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Acp-204 Tartrate
    Bulgaria Czechia France Italy Spain

  • Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Cetuximab
    • Trastuzumab
    Austria Belgium France Germany Greece Hungary +8

  • Study of Valproic Acid, Capecitabine, and Radiotherapy for Patients with Low-Moderate Risk Rectal Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Capecitabine
    • Valproate Semisodium
    Italy

  • Study on the Effectiveness of FOLFIRINOX and FOLFOX for Patients with Advanced Small Bowel Cancer Using Calcium Levofolinate, Irinotecan, and Oxaliplatin

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Small intestine adenocarcinoma
    Investigated Drugs:
    • Calcium Levofolinate
    • Fluorouracil
    • Irinotecan Hydrochloride Trihydrate
    France Italy

  • Study Comparing Odronextamab with Rituximab and Chemotherapy for Patients with Untreated Follicular Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia France Germany Italy +2
Previous Page
1 2 3 4 5 6 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!